NSC Physiological Features in Spinal Muscular Atrophy: SMN Deficiency Effects on Neurogenesis

While the U.S. Food and Drug Administration and the European Medicines Evaluation Agency have recently approved new drugs to treat spinal muscular atrophy 1 (SMA1) in young patients, they are mostly ineffective in older patients since many motor neurons have already been lost. Therefore, understandi...

Descripción completa

Detalles Bibliográficos
Autores principales: Adami, Raffaella, Bottai, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736802/
https://www.ncbi.nlm.nih.gov/pubmed/36499528
http://dx.doi.org/10.3390/ijms232315209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736802/
https://www.ncbi.nlm.nih.gov/pubmed/36499528
http://dx.doi.org/10.3390/ijms232315209

Ejemplares similares